Merck & Co., Inc v Arrow Pharmaceuticals Limited

Link copied
Case Copied 34 min read

OFFICIAL NOTICE

DECISION OF A DEPUTY COMMISSIONER OF PATENTS

Patent:              No. 535944 in the name of Merck & Co., Inc

Title:        Hypocholestermic fermentation products from Aspergillus.

Action:              Request under s.70 for an extension of the term of the patent, and opposition thereto under s.75 by Arrow Pharmaceuticals Limited

Decision:              Issued . 17 April 2002

Abstract

Opposition successful, and the extension refused.

The test for whether a pharmaceutical substance in substance falls within the scope of a claim is intended to be substantially the same as the test under s.102(2)(a) for allowability of amendments. In assessing whether something in substance fell within the scope of a claim, the courts have had regard to the principles of infringement – but this is not a determinative test. Infringements arising from ‘the only reasonable use’ of a substance involve a temporal component arising from when the ‘only reasonable use’ is assessed – and if applied as the test for what in substance fell within the scope of a claim, would introduce a temporal element on the substance of a claim. The Distillers test is appropriate to assess the extent of the infringement required in order for a substance to in substance fall within the scope of a claim. In the present case, while human pharmaceutical use of Lovastatin may reasonably lead to infringement of the claims to its metabolite, an amendment to claim Lovastatin per se would not be allowable as such a claim would give rise to infringement with respect to Lovastatin however used.

The nature of the Australian Register of Therapeutic Goods (ARTG) discussed in detail.

The relationship between s.70(3)(a) and the ARTG discussed. In order for a request to comply with s.70(3)(a), the pharmaceutical substance forming the basis of the request for the extension of term must be included in that part of the ARTG that is publicly accessible – that is, available under reg. 46(2) of the TGA Act. Also, the pharmaceutical substance must also be included in the ARTG as an active ingredient – and, in particular, not merely as an impurity.

PATENTS ACT 1990

DECISION OF A DEPUTY COMMISSIONER OF PATENTS

Re: Patent No. 535944 in the name of Merck & Co., Inc, Request under s.70 for an extension of the term of the patent, and opposition thereto under s.75 by Arrow Pharmaceuticals Limited.

BACKGROUND

  1. This matter concerns a request for an extension of the term of patent 535944 in the name of Merck & Co Inc (Merck), and an opposition thereto by Arrow Pharmaceuticals Limited (Arrow). The matter concerns a substance called Lovastatin, and its b–hydroxy metabolite. Lovastatin is entered on the Australian Register of Therapeutic Goods (ARTG) and is used for the control of cholesterol levels. Lovastatin is a pro-drug which, when administered, is metabolised into the b–hydroxy form that is the substance that directly interacts with the physiological system to produce the therapeutic effect. There is no dispute that such a pro-drug falls within the definition of a pharmaceutical…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Merck & Co., Inc v Arrow Pharmaceuticals Limited and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2002] APO 13
Decision Date

CaseChat Overview and Summary

This case involves a request by Merck & Co., Inc. for an extension of the term of their patent 535944, which was opposed by Arrow Pharmaceuticals Limited. The dispute centres on whether certain conditions under the Patents Act 1990 for extending the term of a pharmaceutical patent are satisfied. Specifically, the court needed to determine if Lovastatin, a substance claimed in Merck's patent, falls within the scope of the patent claims, and whether the substance is listed on the Australian Register of Therapeutic Goods (ARTG) as required by law.

The court examined whether Lovastatin, despite not being explicitly claimed, falls within the scope of the claims for the b-hydroxy metabolite of Lovastatin. The court applied a stringent test, considering whether an amendment to include Lovastatin would be allowable under the Patents Act. The court concluded that while Lovastatin could potentially infringe the claims to the metabolite, it did not substantively fall within the scope of those claims because its inclusion would extend the patent's monopoly rights beyond the intended scope. Additionally, the court found that the b-hydroxy metabolite, while present in the ARTG, was listed as an impurity, not as an active ingredient, thus not meeting the statutory requirement for the extension of the patent term.

The court's decision hinged on a detailed interpretation of the Patents Act and the TGA Act, ensuring that the extension of the patent term aligns with the legislative intent to balance the interests of patentees with public health considerations. The court ultimately refused the request for an extension of the patent term, awarding costs to the opponent.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.